Varian Medical Systems Supports Trial on Lung Cancer Radiosurgery
Varian Medical Systems | April 18, 2016
Varian Medical Systems (NYSE: VAR) announced today it is supporting a phase III trial comparing outcomes of radiosurgery versus surgical resection for the treatment of early-stage, high-risk, operable non-small cell lung cancer (NSCLC).